Sanofi Consumer Healthcare India Designates Two Directors as Senior Management Personnel

2 min read     Updated on 25 Feb 2026, 09:08 PM
scanx
Reviewed by
Radhika SScanX News Team
Overview

Sanofi Consumer Healthcare India Limited's board designated two senior executives as Senior Management Personnel on February 25, 2026. Ms. Nupur Gurbaxani, Director of Brand & Innovation, and Mr. Viral Shah, Director of External Manufacturing, were appointed following Nomination & Remuneration Committee recommendations, with formal regulatory disclosures made to BSE and NSE.

33579270

*this image is generated using AI for illustrative purposes only.

Sanofi Consumer Healthcare India Limited announced the designation of two senior executives as Senior Management Personnel following a board meeting held on February 25, 2026. The decision reflects the company's strategic focus on strengthening its leadership structure across key operational areas.

Board Decision and Regulatory Compliance

The Board of Directors, acting on recommendations from the Nomination & Remuneration Committee, designated Ms. Nupur Gurbaxani and Mr. Viral Shah as Senior Management Personnel effective February 25, 2026. The board meeting commenced at 2:00 p.m. and concluded at 5:20 p.m.

The company made this disclosure pursuant to Regulation 30 read with Para A(7) of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification was sent to both BSE Limited and National Stock Exchange of India Limited as per regulatory requirements.

Senior Management Personnel Details

Executive: Position Joining Date Designation Date
Ms. Nupur Gurbaxani Director, Brand & Innovation July 22, 2024 February 25, 2026
Mr. Viral Shah Director, External Manufacturing May 13, 2024 February 25, 2026

Ms. Nupur Gurbaxani - Brand & Innovation Leadership

Ms. Gurbaxani serves as Director of Brand & Innovation and has been instrumental in driving the company's brand penetration turnaround since joining in July 2024. She brings a consumer-centric approach with sharp insights, innovative campaigns, and digital-first strategies.

An alumna of NMIMS, she possesses over 18 years of extensive experience across leading consumer and healthcare companies including Godrej Consumer Products, Novartis, and Abbott Nutrition. Her expertise positions her to play a critical role in the company's brand transformation and future growth initiatives.

Mr. Viral Shah - Manufacturing Excellence

Mr. Shah holds the position of Director of External Manufacturing and has been driving key infrastructure development initiatives since joining in May 2024. His focus areas include developing partnerships and capabilities to support the company's "Make In India" strategy across product lines.

A graduate of KJ Somaiya Institute of Management, he brings over 20 years of manufacturing and pharmaceutical industry experience from prominent organizations including Torrent, Ranbaxy Laboratories, Merck & Co., and Bayer. His strategic insight and industry expertise are expected to strengthen manufacturing capabilities and accelerate export growth from India.

Strategic Implications

The designation of these executives as Senior Management Personnel underscores Sanofi Consumer Healthcare India's commitment to strengthening its operational leadership. Both appointments align with the company's strategic priorities in brand innovation and manufacturing excellence, positioning the organization for enhanced market performance and growth acceleration. The formal notification to stock exchanges demonstrates the company's adherence to regulatory compliance and transparency standards.

Historical Stock Returns for Sanofi Consumer Healthcare

1 Day5 Days1 Month6 Months1 Year5 Years
-1.44%-5.08%+3.28%-20.31%-12.15%-13.99%
Sanofi Consumer Healthcare
View Company Insights
View All News
like16
dislike

Sanofi Consumer Healthcare India Limited Schedules Board Meeting for February 25, 2026 to Consider Dividend Recommendation

1 min read     Updated on 20 Feb 2026, 03:38 PM
scanx
Reviewed by
Naman SScanX News Team
Overview

Sanofi Consumer Healthcare India Limited has scheduled its Board of Directors meeting for February 25, 2026, to consider dividend recommendations for FY25 ended December 31, 2025, in addition to approving audited financial statements. The company has notified BSE and NSE in compliance with SEBI regulations, with the communication signed by Company Secretary Nikunj Kumar Savaliya on February 20, 2026.

33127706

*this image is generated using AI for illustrative purposes only.

Sanofi Consumer Healthcare India Limited has announced an additional agenda item for its upcoming board meeting, informing stock exchanges about potential dividend considerations for the financial year 2025.

Board Meeting Details

The company has scheduled its Board of Directors meeting for February 25, 2026, which will now include consideration of dividend recommendations alongside the previously announced agenda items.

Meeting Details: Information
Date: February 25, 2026
Day: Wednesday
Primary Agenda: Audited Financial Statements approval
Additional Agenda: Dividend recommendation consideration
Financial Period: Quarter and Year ended December 31, 2025

Regulatory Compliance

The announcement was made in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had previously informed exchanges on February 17, 2026, about the board meeting to consider and approve audited financial statements for the quarter and financial year ended December 31, 2025.

Stock Exchange Communication

Sanofi Consumer Healthcare India Limited has formally notified both major Indian stock exchanges about the expanded meeting agenda:

  • BSE Limited: Scrip Code 544250
  • National Stock Exchange: Symbol SANOFICONR

The communication was signed by Nikunj Kumar Savaliya, Company Secretary and Compliance Officer (Membership No.: F7048), and submitted on February 20, 2026.

Meeting Agenda

The board meeting will address two key items:

  • Consideration and approval of audited financial statements for Q4 and full year ended December 31, 2025
  • Potential recommendation of dividend for the financial year ended December 31, 2025

The company has emphasized that dividend consideration remains subject to board discretion during the scheduled meeting.

Historical Stock Returns for Sanofi Consumer Healthcare

1 Day5 Days1 Month6 Months1 Year5 Years
-1.44%-5.08%+3.28%-20.31%-12.15%-13.99%
Sanofi Consumer Healthcare
View Company Insights
View All News
like20
dislike

More News on Sanofi Consumer Healthcare

1 Year Returns:-12.15%